Jocelyne de Rotrou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jocelyne de Rotrou has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Sophie Rigaud
Hopital Broca, Paris, France
4 shared publications H. Lenoir
2 shared publicationsM. De Sant'Anna
2 shared publications- Véronique Faucounau
Hôpital Broca
2 shared publications Y-H. Wu
2 shared publicationsA Richard
1 shared publication
Latest Publications
- 1 July 2009
- Published by International Society for Gerontechnology (ISG) in Gerontechnology
- Vol. 8 (3) , 185
The LUSAGE Usability laboratory for elderly people with cognitive impairment
The LUSAGE Usability laboratory for elderly people with cognitive impairment
- 1 July 2009
- Published by International Society for Gerontechnology (ISG) in Gerontechnology
- Vol. 8 (3) , 185
The LUSAGE Usability laboratory for elderly people with cognitive impairment
The LUSAGE Usability laboratory for elderly people with cognitive impairment
- 1 October 2008
- Published by International Society for Gerontechnology (ISG) in Gerontechnology
- Vol. 7 (4)
Mental compensation strategies and gerontechnology
- 1 October 2008
- Published by International Society for Gerontechnology (ISG) in Gerontechnology
- Vol. 7 (4)
Mental compensation strategies and gerontechnology
- 23 January 2007
- Published by Wiley in European Journal of Neurology
- Vol. 14 (2) , 144-149
Relevance of 10‐min delayed recall in dementia screening
Within the context of early diagnosis of Alzheimer's disease (AD), there is a growing interest in neuropsychological screening tests. Amongst these tests, we focused on the largely used Memory Impairment Screen (MIS). The objective of the present work was to show that adding a 10‐min delayed recall to the MIS, improves the test psychometric characteristics in order to detect dementia in the earliest stages. A prospective study was carried out on a cohort of 270 consecutive elderly ambulatory subjects attending the Broca Hospital Memory Clinic: normal controls (n = 67), mild cognitive impairment subjects (n = 98) and mildly demented patients [n = 105, Mini Mental State Examination (MMSE) = 23 ± 4]. This study consisted in testing the advantage of the 10‐min delayed recall entitled MIS‐D compared with the MIS. At a cut‐off score of 6, the MIS‐D revealed satisfying psychometric characteristics with a sensitivity of 81% and a specificity of 91%, whilst the MIS alone indicated a sensitivity of 60% and a specificity of 88% in detecting dementia. In demented patients with MMSE score ≥26, MIS‐D properties still remained satisfying (sensitivity: 75%, specificity: 92%). MIS‐D is a more relevant screening test than MIS alone at very early stages of dementia.
- 23 January 2007
- Published by Wiley in European Journal of Neurology
- Vol. 14 (2) , 144-149
Relevance of 10‐min delayed recall in dementia screening
Within the context of early diagnosis of Alzheimer's disease (AD), there is a growing interest in neuropsychological screening tests. Amongst these tests, we focused on the largely used Memory Impairment Screen (MIS). The objective of the present work was to show that adding a 10‐min delayed recall to the MIS, improves the test psychometric characteristics in order to detect dementia in the earliest stages. A prospective study was carried out on a cohort of 270 consecutive elderly ambulatory subjects attending the Broca Hospital Memory Clinic: normal controls (n = 67), mild cognitive impairment subjects (n = 98) and mildly demented patients [n = 105, Mini Mental State Examination (MMSE) = 23 ± 4]. This study consisted in testing the advantage of the 10‐min delayed recall entitled MIS‐D compared with the MIS. At a cut‐off score of 6, the MIS‐D revealed satisfying psychometric characteristics with a sensitivity of 81% and a specificity of 91%, whilst the MIS alone indicated a sensitivity of 60% and a specificity of 88% in detecting dementia. In demented patients with MMSE score ≥26, MIS‐D properties still remained satisfying (sensitivity: 75%, specificity: 92%). MIS‐D is a more relevant screening test than MIS alone at very early stages of dementia.
- 1 December 2006
- Vol. 32
[Stress, Alzheimer's disease and psychotherapy].
- 1 July 1999
- Published by Wiley in European Journal of Neurology
- Vol. 6 (4) , 415-421
Apolipoprotein E phenotypes in demented and cognitively impaired patients with and without cerebrovascular disease
Controversy exists regarding the apolipoprotein E (ApoE) ɛ4 allele association with vascular dementia (VaD), ranging from increased ɛ4 frequency, similar to that found for Alzheimer's disease (AD), to no association between the ɛ4 allele and VaD. To clarify further the relationship between ApoE alleles polymorphism and cerebrovascular disease (CVD) in demented and cognitively impaired patients, we examined the ApoE phenotypes in a sample of 280 patients: 155 with AD, 21 with VaD, 32 with mixed dementia (MD), 45 with mild cognitive impairment (MCI) but without CVD, and 27 in which vascular disease was the most probable cause of cognitive decline [vascular mild cognitive impairment (VMCI)]. Our results show that the frequency of the ApoE ɛ4 allele in patients over 70 years old with clinically diagnosed VaD and VMCI does not differ significantly from that of controls. In contrast, ApoE ɛ4 allele‐bearing individuals had greater risk of having late‐onset AD (OR=8.8; 95% Cl 3.7–21.0), or non‐vascular cognitive impairment (OR=7.0; 95% Cl 2.5–19.0).
- 1 July 1999
- Published by Wiley in European Journal of Neurology
- Vol. 6 (4) , 415-421
Apolipoprotein E phenotypes in demented and cognitively impaired patients with and without cerebrovascular disease
Controversy exists regarding the apolipoprotein E (ApoE) ɛ4 allele association with vascular dementia (VaD), ranging from increased ɛ4 frequency, similar to that found for Alzheimer's disease (AD), to no association between the ɛ4 allele and VaD. To clarify further the relationship between ApoE alleles polymorphism and cerebrovascular disease (CVD) in demented and cognitively impaired patients, we examined the ApoE phenotypes in a sample of 280 patients: 155 with AD, 21 with VaD, 32 with mixed dementia (MD), 45 with mild cognitive impairment (MCI) but without CVD, and 27 in which vascular disease was the most probable cause of cognitive decline [vascular mild cognitive impairment (VMCI)]. Our results show that the frequency of the ApoE ɛ4 allele in patients over 70 years old with clinically diagnosed VaD and VMCI does not differ significantly from that of controls. In contrast, ApoE ɛ4 allele‐bearing individuals had greater risk of having late‐onset AD (OR=8.8; 95% Cl 3.7–21.0), or non‐vascular cognitive impairment (OR=7.0; 95% Cl 2.5–19.0).